Ultragenyx (RARE) director granted RSUs and stock options as compensation

Q: When do Ray Amrit’s new Ultragenyx (RARE) RSUs and options vest?

The RSUs and options vest on a single future date trigger. They vest in full on the earlier of Ultragenyx’s next Annual Meeting of Stockholders or May 14, 2027, aligning director compensation with the company’s governance timeline.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. director Ray Amrit reported new equity awards consisting of both restricted stock units and stock options. He received 7,751 shares of Common Stock as Restricted Stock Units granted under the Company’s 2023 Incentive Plan. After this award, he directly holds 31,116 shares of Common Stock.

Amrit was also granted a stock option covering 14,058 shares of Common Stock at an exercise price of $25.80 per share, expiring on May 14, 2036. Both the RSUs and the option vest in full on the earlier of the Company’s next Annual Meeting of Stockholders or May 14, 2027, making this a routine, compensation-related acquisition rather than an open-market purchase.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ray Amrit

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	14,058	$0.00	--
Grant/Award	Common Stock	7,751	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 14,058 shares (Direct, null); Common Stock — 31,116 shares (Direct, null)

Footnotes (1)

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

Key Figures

RSU grant: 7,751 shares Common shares after grant: 31,116 shares Option grant size: 14,058 shares +3 more

6 metrics

RSU grant 7,751 shares Restricted Stock Units under 2023 Incentive Plan

Common shares after grant 31,116 shares Direct common stock holdings following RSU award

Option grant size 14,058 shares Stock Option (Right to Buy) underlying common shares

Option exercise price $25.80/share Conversion or exercise price of stock option

Option expiration May 14, 2036 Expiration date of stock option grant

Vesting trigger date May 14, 2027 Latest vesting date for RSUs and option, or earlier annual meeting

Key Terms

Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy)

3 terms

Restricted Stock Units ("RSUs") financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2023 Incentive Plan financial

"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with underlying security title Common Stock."

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 06:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ray Amrit

(Last)

(First)

(Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO

CALIFORNIA

94949

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A		7,751⁽¹⁾	A	$0	31,116	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$25.8	05/14/2026		A		14,058		⁽²⁾	05/14/2036	Common Stock	14,058	$0	14,058	D

Explanation of Responses:

1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

2. The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027.

	/s/ Karah Parschauer, attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ultragenyx (RARE) director Ray Amrit report?

Ray Amrit reported receiving equity awards from Ultragenyx. He was granted 7,751 restricted stock units and a stock option for 14,058 shares of Common Stock, both as compensation awards rather than open-market purchases or sales.

How many Ultragenyx (RARE) shares does Ray Amrit hold after this grant?

After the award, Ray Amrit holds 31,116 common shares directly. This reflects the updated ownership following the grant of 7,751 restricted stock units, as disclosed in the filing, and excludes the 14,058 underlying option shares not yet exercised.

What are the key terms of Ray Amrit’s new stock options at Ultragenyx (RARE)?

Ray Amrit received options for 14,058 shares at $25.80 per share. These options relate to Ultragenyx Common Stock, carry an expiration date of May 14, 2036, and represent a compensation grant rather than a market transaction.

When do Ray Amrit’s new Ultragenyx (RARE) RSUs and options vest?

The RSUs and options vest on a single future date trigger. They vest in full on the earlier of Ultragenyx’s next Annual Meeting of Stockholders or May 14, 2027, aligning director compensation with the company’s governance timeline.

Are Ray Amrit’s Ultragenyx (RARE) equity awards open-market purchases or compensation grants?

The reported transactions are compensation-related grants, not open-market trades. Both the 7,751 restricted stock units and the 14,058-share stock option were awarded under Ultragenyx’s 2023 Incentive Plan as part of director compensation.